Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 842)

[megawurst]

Antwort auf Beitrag Nr.: 50.596.196 von techinvestor69 am 10.09.15 13:52:18

Naja, dann werde ich mal versuchen noch ein paar Stücke zu bekommen. Also 70 cents, ca. 100 MM Dollar wäre dann erstmal das erste Ziel

[techinvestor69]

Erstmal über 100 Mio. marketcap, dann Wechsel an TSX, dann 250 Mio. marketcap, dann Nasdaq, dann 1 Mrd. USD - soweit mein feuchter Traum.

[megawurst]

Antwort auf Beitrag Nr.: 50.595.581 von M@trix am 10.09.15 12:43:42

Ja, die Geschichte macht einen soliden Eindruck. Hat Irgendjemand ne Prognose wo das Ding hingehen wird ?

[techinvestor69]

47,4 Mio. CAD (nicht USD) als Börsenwert finde ich aktuell und nach DEN heutigen News beileibe nicht zu teuer!!!

Vorallem wenn ich sehe, was ein privates Unternehmen, das noch weit hinter Sernova ist, in dem Bereich eingesammelt hat - nämlich 44 Mio. USD:
https://www.bostonglobe.com/business/2015/03/23/biotech-star…

0,18 CAD Finanzierung lief, um strategische Investoren zu platzieren, wie ich gehört habe. Denke nicht, dass diese Stücke herausfallen.

Sernova ist auf dem Weg zum nächsten Level.

[M@trix]

Hallo techinvestor69,

nach meiner Einschätzung wird die Aktie in den nächsten Wochen wieder zurückkommen.

In 5 Tagen endet die Haltefrist für die Aktien und Warrants aus der Kapitalerhöhung im Mai und sicher werden einige Kasse machen.

Insofern würde ich eher mal Gewinne realisieren - es sei denn, man ist hier mit einer Perspektive von Jahren investiert. Die Technologie ist unzweifelhaft spannend, aber noch lange entfernt vom Markteintritt:



Beste Grüße

M@trix

[techinvestor69]

News out!!!!!!!!!! The party is about to begin!

Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies

V.SVA | 18 minutes ago
UHN (University Health Network) agreement transitions Sernova to an integrated therapeutic cell regenerative medicine Company

LONDON, ONTARIO--(Marketwired - Sept. 10, 2015) - Sernova Corp. (TSX VENTURE:SVA)(FRANKFURT:PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, announced today it has signed a license agreement with the University Health Network (UHN) of Toronto, Canada to gain exclusive worldwide rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. These technologies relate to the development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.

"This agreement provides us with a proprietary source of stem cell derived glucose responsive therapeutic cells. When placed within Sernova's prevascularized Cell Pouch™, and protected locally from immune system attack, we believe that Sernova has the potential to provide a significant break-through in the quality of treatment for the millions of people suffering from insulin-dependent diabetes," said Dr. Philip Toleikis, Sernova's President and CEO. "Such individuals could essentially be liberated from their current onerous daily regime of multiple blood glucose testing and insulin administration delivered through injections or electronic means which is expected to materially improve their quality of life, prevent or reduce abnormal glucose complications, and reduce short term and longer term health care costs."

The current standard of care for islet transplantation is limited to diabetic patients with severe hypoglycemia unawareness due to both a lack of cadaveric donor islets and a requirement for life-long use of toxic anti-rejection drugs.

"We believe that a virtually unlimited supply of glucose responsive therapeutic cells could be generated from ethically derived stem cells which, if shown to have positive safety and efficacy in clinical trials, could be used to treat millions of patients," commented Delfina Siroen, Sernova's head of Research and Development. "The addition of the UHN stem cell technologies moves Sernova one step further toward being able to provide a full solution (device, unlimited cell supply and local immune protection) for cell therapy applications."

About Diabetes

The worldwide incidence of diabetes is approximately 370 million. Sernova's potential addressable market which includes Type-1 patients and those Type-2 patients requiring insulin is over 30 million people. Although there is currently no cure for diabetes, blood glucose levels are being controlled with frequent blood glucose testing combined with regular injections of insulin via syringe or insulin pump; however, blood glucose control using this treatment approach can be poor, leading to side effects such as heart, kidney and eye diseases as well as ischemia-induced amputations. According to the Juvenile Diabetes Research Foundation, annual health care costs for the treatment of diabetes and its debilitating side effects are estimated to be over US $245 billion per year in North America (http://jdrf.org/).

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch™, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

Read more at http://www.stockhouse.com/news/press-releases/2015/09/10/ser…

[techinvestor69]

Gutes Interesse heute auch in Deutschland.

Gap bei 0,315/0,32 wurde heute zu gemacht. Chart wieder sauber.

[techinvestor69]

Glückwunsch an Mitgliedschaft! Super Fund! Und die Story geht erst los!

[techinvestor69]

wow!!!!!!!!!!!!!!!!!!!!

0,40 CAD hoch

Aktuell 0,35 CAD - neues Jahreshoch!!!!!! Sauber!!!!!!

Roadshow läuft ja gut an.

[Tuedi]

Wäre ja schon geil, wenn Sernova nochmal ein Stück zurück kommen würde...

Super Aussichten - da juckt es ja schon, zu kaufen.